Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

US Patent 11639927 · Granted May 2, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods and kits for predicting infusion reaction risk and antibody-mediated los2025
Methods and kits for predicting infusion reaction risk and antibody-mediated los2025
Methods and kits for predicting infusion reaction risk and antibody-mediated los2024
Methods and kits for predicting infusion reaction risk and antibody-mediated los2024
Methods and kits for predicting infusion reaction risk and antibody-mediated los2023
Methods and kits for predicting infusion reaction risk and antibody-mediated los2023
Methods and kits for predicting infusion reaction risk and antibody-mediated los2020
Methods and kits for predicting infusion reaction risk and antibody-mediated los2020
Methods and kits for predicting infusion reaction risk and antibody-mediated los2018
Methods and kits for predicting infusion reaction risk and antibody-mediated los2018
Methods and kits for predicting infusion reaction risk and antibody-mediated los2016
Methods and kits for predicting infusion reaction risk and antibody-mediated los2016